


Care Planning Process





HIGH-RISK PATIENTS

5% of patients; usually with complex disease(s), comorbidities

RISING-RISK PATIENTS

~35% of patients; may have conditions not optimally managed

LOW RISK PATIENTS

~60% of patients; with minor transient conditions which are easily managed

15% - 35% of rising risk patients may not have their conditions optimally managed.



Search this site





ABOUT CPGS PATIENTS MEDICAL HOME HEALTH NEIGHBOURHOOD **EMR SUPPORTS EVENTS & TRAINING**

♠ > Patients Medical Home > Patient Centered Interactions

PaCT

Tools and Resources

Evaluation and Measurement

PaCT Webinars

Patients Collaborating with Teams

Overnew

Patients Collaborating with Teams (PaCT) takes a proactive, systematic approach to enable patient to manage their care when they have, or are at risk for having, multiple chronic diseases or other complex health needs. PaCT takes the next step in the patient's medical home by furthering the panel and chronic disease management work already underway in PCNs and primary care clinics.

Panel and Continuity





At the heart of PaCT, providers and their teams are supported to reach those patients that keep them up at night by shifting the conversation from, "What's the matter?" to "What matters to you?"

- · Advances in evidence-based medicine create opportunities to improve care for patients with complex health needs
- · Practice-level collaborative care-planning approaches are effective in supporting patients with complex health needs
- · Research tells us that using team-based care improves patient outcomes
- . 'Many hands make light work': when teams share skills and knowledge to care for those with complex health needs, the work is not as challenging for any one
- · Alberta data indicates that many practices have a significant number of patients with complex health needs who do not seek adequate care
- · PaCT will build on panel identification and maintenance processes already embedded in practices and facilitate the spread of excellent care processes to all primary care practices.

Read PaCT's one pager or FAQ for more information. Or watch the following videos to learn more about PaCT:

- What is PaCT?
- · The benefits of care planning with patients
- · PaCT: What is the evidence?
- Care Planning: The Patient Experience
- How Care Planning has Changed




Refer to

Printed

Care Planning Template

This accument was created on: "GINNERY I LIANTER and aust updated on: "AUT-LIANTE LIANTER LIANTER AND CARE Planning Visit Introduction to Your Care Plan and Care plan's will be filled out by you and you Introduction to Your Care Plan as care plan's will be filled out by you and you Introduction to Your Care Plan as care plan's will be filled out by you and you Introduction to Your Care Plan and Care plan's will be filled out by you and you plants the course of this you.





Tools to Support Safer Prescribing

Refer to
Printed
Materials

List of tools in IF package





Opioid Use Disorder Primary Care Pathway




Consider Prescription Opioid Misuse Index (POMI) if patient receives prescription opioids and OUD is suspected.

Yes to ≥2 means diagnosis is more likely. If not, it is less likely.

DO YOU EVER:

- ☐ Use your medication more often, (shorten the time between doses), than prescribed?
- ☐ Use more of your medication, (take a higher doses) than prescribed?
- □ Need early refills for your pain medications?
- ☐ Feel high or get a buzz after using your pain medication?
- ☐ Take your pain medication because you are upset, to relieve or cope with problems other than pain?
- ☐ Go to multiple physicians /emergency room doctors, seeking more of your pain medication?



PRACTICE PEARLS

- · Naloxone kits should be provided to all patients who are prescribed OAT.
- · Avoid punitive measures. Continued drug use could suggest a need for treatment intensification.
- · Stabilizing OUD may help with the management of chronic pain.

TREATMENT CONSIDERATIONS

Tailored to patient's needs and disease stability.

Treatment Agreement (Contract)

To outline patient and provider expectations.

Urine Drug Testing

May be required by provincial regulations.

- * Most trials report on retention in OAT treatment. While RCT data is limited on patient oriented outcomes, observational data suggests retention in treatment is associated with reduction in mortality and improvement in quality of life.
- † Eg. Injectable naltrexone (opioid antagonist that requires 7-10 day opioid free period) not currently available in Canada, slow release morphine.

Korownyk C, Perry D, Ton J, Kolber MR, Garrison S, Thomas B, et al. Managing opioid use disorder in primary care, PEER simplified guideline, Can Fam Physician 2019:65:321-30.





Patient Should be in Opioid Withdrawal

COWS Score >12

(~12-24 hours after last opioid dose)

Give BUP/NLX 4mg/1mg

WAIT 60 MIN.

Withdrawal

Symptoms Gone

or 4mg/1mg*

BUP/NLX 12mg/3mg on Day 1

Yes

 $\overline{}$

May increase dose by a maximu of 4mg/1mg each day

24mg/6mg per day)

Wait 1-3

hours

Day 1

Yes

Day 1 Dose

Day 2 and onward

Buprenorphine/Naloxone (BUP/NLX) PEER Induction Flow Diagram

Significantly Worse

(Only after first dose)

Possible Precipitated

1. Patient can stop and try

2. Patient can continue

3. Clinicians may treat

with medications.

withdrawal symptoms

*Can send

patient home

with 2-4 tablets

(2mg/0.5mg) to

finish induction.

•

Take the

same dose as

yesterday

induction again tomorrow

Withdrawal

induction.

Withdrawal symptoms present before dose?



Refer to

Printed



Resting Pulse Rate Sweating Observed Restlessness Pupil Size 0 1 2 Bone or Joint Aches 0 1 2 Runny Nose 0 1 2 or Tearing Gastrointestinal 0 1 2 Upset Observed Tremor of Outreached Hands Observed Yawning Anxiety or Irritability Gooseflesh Skin TOTAL SCORE

Agents for Management of Withdrawal Symptoms (Including precipitated withdrawal)

	•
Symptom ▶ Agent	DIRECTIONS
Anxiety Clonidine	0.1mg PO Q4H PRN
Anxlety ▶ Quetiapine	25mg PO QHS PRN
Sleep Trazodone	50-100mg PO QHS PRN
Patn • Ibuprofen	600mg PO Q6H PRN
Nausea Dimenhydrinate	50mg PO Q6H PRN
Nausea Ondanestron	4mg PO Q6H PRN
Diarrhea Loperamide	4mg, followed by 2mg after each loose stool (max:16mg/day)

† Full COWS Scoring Available at: https://www.drugabuse.gov/sites/default/files/files/ClinicalOpiateWithdrawalScale.pdf For home induction, use patient administered Subjective Opiate Withdrawal Scale (SOWS) scoring available at: http://www.bcsu.ca/wp-content/uploads/2017/08/SOWS.pdf





Opioid Provider-Patient Conversation

Checklist



Refer to Printed Materials

Used to ensure that both patient and provider have a mutual understand of opioid therapy

Opioid Risk Tool



Mark each box that applies	Female	Male			
Family history of substance abuse					
Alcohol	1	3			
Illegal drugs	2	3			
Rx drugs	4	4			
Personal history of substance abuse					
Alcohol	3	3			
Illegal drugs	4	4			
Rx drugs	5	5			
Age between 16—45 years	1	1			
History of preadolescent sexual abuse	3	0			
Psychological disease					
ADD, OCD, bipolar, schizophrenia	2	2			
Depression	1	1			
Scoring totals					

Used to look for patient risk factors prior to prescribing opioid therapy

Adverse Childhood Experiences (ACEs) Questionnaire



PrimaryCare

CALGARY FOOTHILLS

- 1. A parent or other adult in the household would often swear at me, insult me, put me down, or humiliate me OR act in a way that made me afraid that I might be physically hurt
- 2. A parent or other adult in the household would often push, grab, slap or throw something at me OR hit me so hard that I had marks or was injured
- 3. An adult or person at least 5 years older than me touch or fondled me or had me tough their body in a sexual way OR tried to have oral, anal or vaginal intercourse with me
- 4. I often felt that no one in my family loved me or thought I was important or special OR that my family didn't look out for each other, feel close to each other, or support each other
- 5. I often felt that I didn't have enough to eat, had to wear dirty clothes, and had no one to protect me OR my parents were too drunk or high to take care of me or take me to the doctor id I needed it
- 6. I experienced a parental death, separation or divorce
- 7. A household member was often pushed, grabbed, slapped, or had something thrown at him/her OR sometimes kicked, bitten, hit with a fist, or something hard OR ever repeatedly hit over at least a few minutes or threatened with a gun or knife
- 8. I lived with someone who was a problem drinker or alcoholic, or who used street drugs
- 9. A household member was depressed, mentally ill, or attempted suicide
- 10. A household member went to prison

Your ACE score is the total number of 'yes' answers

Prescription Opioid Misuse Index (POMI)



2 "yes" answers indicates a positive screen

- 1. Do you ever use **more of your medication**, that is, take a higher dose, than is prescribed for you?
- 2. Do you ever use your medication **more often**, that is, shorten the time between doses, than is prescribed for you?
- 3. Do you ever need **early refills** for your pain medication?
- 4. Do you ever **feel high or get a buzz** after using your pain medication?
- 5. Do you ever take your pain medication because you are upset, using the medication to relieve or cope with problems other than pain?
- 6. Have you ever **gone to multiple physicians**, including emergency room doctors, seeking more of your pain medication?

Used to screen patients for possible Opioid Use Disorder

COVS

SOV	VS	Patient's Medical Hom

Patient's Medical Home	e

Patient's Name:	Date and Time/:				
Reason for this assessment					
Resting Pulse Rate:beats/minute Measured after patient is sitting or lying for one minute	GI Upset: over last 1/2 hour 0 no GI symptoms				
0 pulse rate 80 or below	1 stomach cramps				
1 pulse rate 81-100	2 nausea or loose stool				
2 pulse rate 101-120	3 vomiting or diarrhea				
4 pulse rate greater than 120	5 multiple episodes of diarrhea or vomiting				
Sweating: over past 1/2 hour not accounted for by	Tremor observation of outstretched hands				
room temperature or patient activity.	0 no tremor				
0 no report of chills or flushing	1 tremor can be felt, but not observed				
1 subjective report of chills or flushing	2 slight tremor observable				
2 flushed or observable moistness on face	4 gross tremor or muscle twitching				
3 beads of sweat on brow or face	-				
4 sweat streaming off face					
Restlessness Observation during assessment	Yawning Observation during assessment				
0 able to sit still	0 no yawning				
1 reports dif ficulty sitting still, but is able to do so	1 yawning once or twice during assessment				
3 frequent shifting or extraneous movements of legs/arms	2 yawning three or more times during assessment				
5 unable to sit still for more than a few seconds	4 yawning several times/minute				
Pupil size	Anxiety or Irritability				
0 pupils pinned or normal size for room light	0 none				
I pupils possibly larger than normal for room light	1 patient reports increasing irritability or anxiousness				
2 pupils moderately dilated	2 patient obviously irritable or anxious				
5 pupils so dilated that only the rim of the iris is visible	4 patient so irritable or anxious that participation in the assessment is difficult				
Bone or Joint aches If patient was having pain	Gooseflesh skin				
previously, only the additional component attributed	0 skin is smooth				
to opiates withdrawal is scored	3 pil oerrection of skin can be felt or hairs standing up				
0 not present	onarms				
1 mild diffuse discomfort	5 prominent piloerrection				
2 patient reports severe diffuse aching of joints/muscles 4 patient is rubbing joints or muscles and is unable to sit					
still because of discomfort					
Runny nose or tearing Not accounted for by cold					
symptoms or allergies	Total Score				
0 not present	The total score is the sum of all 11 items				
1 nasal stuffiness or unusually moist eyes	The total score is the sum of all 11 items				
2 nose running or tearing	Initials of person				
4 nose constantly running or tears streaming down cheeks	completing assessment:				

Score: 5-12 = mild; 13-24 = moderate; 25-36 = moderately severe; more than 36 = severe withdrawal

This version may be copied and used clinically.

SUBJECTIVE OPIATE WITHDRAWAL	SCALE
(5	ows)

The SOWS is a self-administered scale for grading opioid withdrawal symptoms. It contains 16 symptoms whose intensity the patient rates on a scale of 0 (not at all) to 4 (extremely), and takes less than 10 minutes to complete.

Patient Instructions: please score each of the 16 items below according to how you feel right now. Circle one number only.

Item	Symptom	Not at all	A little	Moderately	Quite a bit	Extremely
1	I feel anxious	0	1	2	3	4
2	I feel like yawning	0	1	2	3	4
3	I am perspiring	0	1	2	3	4
4	My eyes are teary	0	1	2	3	4
5	My nose is running	0	1	2	3	4
6	I have goosebumps	0	1	2	3	4
7	I am shaking	0	1	2	3	4
8	I have hot flushes	0	1	2	3	4
9	I have cold flushes	0	1	2	3	4
10	My bones and muscles ache	0	1	2	3	4
11	I feel restless	0	1	2	3	4
12	I feel nauseous	0	1	2	3	4
13	I feel like vomiting	0	1	2	3	4
14	My muscles twitch	0	1	2	3	4
15	I have stomach cramps	0	1	2	3	4
16	I feel like using now	0	1	2	3	4

Total	Score:			

SUBSTANCE USE

Menu

Introduction
 Acknowlegements

Learning Objectives

- OAT Shared Decision
 CPSA Requirements
- ▶ Treatment Spectrum
- Opioid Withdrawal Syndrome
- Assessing for Opioid Withdrawal
- Withdrawal Management

Summary - video

Knowledge Check


Conclusion

AHS PACES training

https://www.albertahealthse rvices.ca/info/page16083.as px Alberta ODT Module 5_Part 1



Learning Objectives:



Upon conclusion of this module, the following learning objectives will be accomplished:

- Define opioid agonist treatment and how it aligns with the spectrum of treatment intensity
- 2. Explain medically assisted withdrawal treatment
- Describe 1st line vs 2nd line treatment recommendations for OAT Therapy
- Compare and contrast Buprenorphine/Naloxone and Methadone
- Practice in a simulated environment how to successfully complete a:
 - Methadone induction
 - Buprenorphine/Naloxone home induction
 - Conversion from full agonist to partial agonist (methadone to Buprenorphine/Naloxone)

